Rankings
▼
Calendar
BIIB Q4 2021 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena
BIIB
Biogen Inc.
$28B
Q4 2021 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$2.7B
-4.2% YoY
Gross Profit
$2.1B
75.9% margin
Operating Income
$507M
18.5% margin
Net Income
$368M
13.5% margin
EPS (Diluted)
$2.50
QoQ Revenue Growth
-1.6%
Cash Flow
Operating Cash Flow
$838M
Free Cash Flow
$770M
Stock-Based Comp.
$59M
Balance Sheet
Total Assets
$23.9B
Total Liabilities
$12.9B
Stockholders' Equity
$10.9B
Cash & Equivalents
$2.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.7B
$2.9B
-4.2%
Gross Profit
$2.1B
$2.4B
-12.2%
Operating Income
$507M
-$331M
+253.3%
Net Income
$368M
$358M
+2.9%
Revenue Segments
MS Product Revenues
$1.5B
44%
Fumarate
$611M
18%
TYSABRI product
$513M
15%
SPINRAZA
$441M
13%
Interferon
$378M
11%
Geographic Segments
Non-US
$1.2B
56%
UNITED STATES
$955M
44%
← FY 2021
All Quarters
Q1 2022 →